Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

被引:113
|
作者
Freites Nunez, Dalifer D. [1 ,2 ]
Leon, Leticia [1 ,2 ,3 ]
Mucientes, Arkaitz [1 ,2 ]
Rodriguez-Rodriguez, Luis [1 ,2 ]
Font Urgelles, Judit [4 ]
Madrid Garcia, Alfredo [1 ,2 ]
Colomer, Jose, I [1 ,2 ]
Jover, Juan A. [4 ,5 ]
Fernandez-Gutierrez, Benjamin [4 ]
Abasolo, Lydia [1 ,2 ]
机构
[1] Fdn Invest Biomed Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain
[2] Fdn Invest Biomed Hosp Clin San Carlos, IDISSC, Madrid, Spain
[3] Univ Camilo Jose Cela, Dept Hlth & Educ, Madrid, Spain
[4] Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain
[5] Univ Complutense Madrid, Med Dept, Madrid, Comunidad De Ma, Spain
关键词
CORONAVIRUS;
D O I
10.1136/annrheumdis-2020-217984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19. Methods An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission. Results The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model. Conclusion Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.
引用
收藏
页码:1393 / 1399
页数:7
相关论文
共 50 条
  • [11] Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases
    Bachiller-Corral, Javier
    Boteanu, Alina
    Jesus Garcia-Villanueva, Maria
    de la Puente, Carlos
    Revenga, Marcelino
    Consuelo Diaz-Miguel, M.
    Rodriguez-Garcia, Ana
    Luis Morell-Hita, Jose
    Valero, Marta
    Larena, Carmen
    Blazquez-Canamero, Maria
    Guillen-Astete, Carlos A.
    Garrote, Sandra
    Sobrino, Cristina
    Medina-Quinones, Carmen
    Vazquez-Diaz, Monica
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1098 - 1102
  • [12] Clinical outcomes and risk factors in patients with COVID-19 and autoimmune rheumatic diseases: insights from a major Australian hospital study
    Ling, Zhi
    Guy, Stephen
    Fong, Christopher
    INTERNAL MEDICINE JOURNAL, 2024, 54 (10) : 1634 - 1643
  • [13] COVID-19 and autoimmune rheumatic diseases
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2020, 2 (10): : E593 - E593
  • [14] Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
    Pablos, Jose L.
    Abasolo, Lydia
    Alvaro-Gracia, Jose M.
    Blanco, Francisco J.
    Blanco, Ricardo
    Castrejon, Isabel
    Fernandez-Fernandez, David
    Fernandez-Gutierrez, Benjamin
    Galindo-Izquierdo, Maria
    Gonzalez-Gay, Miguel A.
    Manrique-Arija, Sara
    Mena Vazquez, Natalia
    Mera Varela, Antonio
    Retuerto, Miriam
    Seijas-Lopez, Alvaro
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (09) : 1170 - 1173
  • [15] Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases
    Furer, Victoria
    Rondaan, Christien
    Agmon-Levin, Nancy
    van Assen, Sander
    Bijl, Marc
    Kapetanovic, Meliha Crnkic
    de Thurah, Annette
    Mueller-Ladner, Ulf
    Paran, Daphna
    Schreiber, Karen
    Warnatz, Klaus
    Wulffraat, Nico M.
    Elkayam, Ori
    RMD OPEN, 2021, 7 (01):
  • [16] Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Diseases
    Balbuena, Silera Holguin
    Radisic, Anna
    Goodman, Sarah
    Gor, Shreya
    Wood, Beatrice
    Shahin, Alexander
    Samuel, Kelara
    Mhaskar, Rahul
    Carter, John
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2631 - 2633
  • [17] CHARACTERISTICS OF PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES AND COVID-19 ADMITTED TOA SENTINEL HOSPITAL
    Santos, Vladimir Aroja
    Flores, Jaime Omar Velasco
    Garcia, Indira Mendez
    Aruquipa, Grisel Arminda Lipa
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S48 - S49
  • [18] A RETROSPECTIVE ANALYSIS OF COVID-19 PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES IN A MAJOR AUSTRALIAN HOSPITAL
    Ling, Zhi
    Liu, Ruijien
    Guy, Stephen
    Fong, Christopher
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 21 - 21
  • [19] IDENTIFICATION OF FACTORS ASSOCIATED WITH THE OCCURRENCE OF SEVERE FORMS OF COVID-19 INFECTION IN PATIENTS WITH AUTOIMMUNE/INFLAMMATORY RHEUMATIC DISEASES
    Chevalier, K.
    Genin, M.
    Jean, T. Petit
    Avouac, J.
    Flipo, R. M.
    Georgin-Lavialle, S.
    El Mahou, S.
    Pertuiset, E.
    Pham, T.
    Servettaz, A.
    Marotte, H.
    Domont, F.
    Chazerain, P.
    Devaux, M.
    Mekinian, A.
    Sellam, J.
    Fautrel, B.
    Rouzaud, D.
    Ebstein, E.
    Costedoat-Chalumeau, N.
    Richez, C.
    Hachulla, E.
    Mariette, X.
    Seror, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1682 - 1683
  • [20] COVID-19 Among Patients With Inflammatory Rheumatic Diseases
    Esatoglu, Sinem Nihal
    Tascilar, Koray
    Babaoglu, Hakan
    Bes, Cemal
    Yurttas, Berna
    Akar, Servet
    Pehlivan, Ozlem
    Akleylek, Cansu
    Tecer, Duygu
    Seyahi, Emire
    Yuce-Inel, Tuba
    Alpay-Kanitez, Nilufer
    Bodakci, Erdal
    Tekgoz, Emre
    Colak, Seda
    Bolek, Ertugrul Cagri
    Koca, Suleyman Serdar
    Kalyoncu, Umut
    Icacan, Ozan Cemal
    Ugurlu, Serdal
    Oz, Hande Ece
    Hamuryudan, Vedat
    Hatemi, Gulen
    FRONTIERS IN IMMUNOLOGY, 2021, 12